Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBT (2016 - 2025)

Historic EBT for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $71.0 million.

  • Catalyst Pharmaceuticals' EBT rose 2417.62% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $285.8 million, marking a year-over-year increase of 5138.33%. This contributed to the annual value of $216.3 million for FY2024, which is 12882.31% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported EBT of $71.0 million as of Q3 2025, which was up 2417.62% from $69.3 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBT peaked at $74.2 million during Q4 2024, and registered a low of -$38.0 million during Q3 2023.
  • Its 5-year average for EBT is $35.8 million, with a median of $33.0 million in 2022.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' EBT plummeted by 24619.53% in 2023, and later surged by 25045.63% in 2024.
  • Catalyst Pharmaceuticals' EBT (Quarter) stood at $12.8 million in 2021, then surged by 157.61% to $33.0 million in 2022, then surged by 41.5% to $46.7 million in 2023, then soared by 58.82% to $74.2 million in 2024, then decreased by 4.24% to $71.0 million in 2025.
  • Its EBT stands at $71.0 million for Q3 2025, versus $69.3 million for Q2 2025 and $71.3 million for Q1 2025.